Disclosure of Conversion of 305000 Warrants into Equity Shares belonging to Promoter and Non Promoter Category

Date: 18th August, 2026 Corporate Services Department, BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 540204 Subject: Disclosure of Conversion of Warrants into Equity Shares under the Securi(cid:415)es and Exchange Board of India (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements), Regula(cid:415)ons 2015 (“SEBI LODR Regula(cid:415)ons”) Ref: Company’s announcement dated 24th February, 2026 in rela(cid:415)on with Allotment of Warrants and Extra- Ordinary General Mee(cid:415)ng dated 07th January, 2026 In con(cid:415)nua(cid:415)on to the le(cid:425)er dated 24th February, 2026, w.r.t. to allotment of Warrants, in terms of Regula(cid:415)on 30 of the SEBI (LODR) Regula(cid:415)ons, we wish to inform you that the Board of Directors of the Company vide Circular Resolu(cid:415)on today, i.e. Tuesday, 18th August, 2026, considered and approved the allotment of equity shares on conversion of 3,05,000 (Three Lakh Five Thousand) Warrants into 3,05,000 (Three Lakh Five Thousand) Equity Shares at an issue price of Rs. 55/- (Rupees Fi(cid:332)y-Five only) (including a premium of Rs. 45/-) each, to person belonging to the Promoter and Non-Promoter Category, on preferen(cid:415)al basis, upon receipt of amount aggrega(cid:415)ng to Rs. 1,25,81,250/- (Rupees One Crore Twenty-Five Lakh Eighty-One Thousand Two Hundred Fi(cid:332)y Only) (being 75% of the issue price per Warrants) at the rate of Rs. 55/- (Rupees Fi(cid:332)y-Five only) per Warrant from the allo(cid:425)ee pursuant to the exercise of his rights of conversion into equity shares in accordance with the provisions of Securi(cid:415)es and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regula(cid:415)ons, 2018. Following are the details of the allo(cid:425)ees: Sr. Name of Category No. of No. of No. of Amount received No. of N Allo(cid:425)ee (Promote warrants warrants Equity being 75% of the warrants o r held applied for Shares issue price per pending for or Non- (prior to conversion allo(cid:425)ed warrant conversion Promoter conversion) 1. Bhavesh Promoter 15,50,000 1,30,000 1,30,000 Rs. 53,62,500 14,20,000 Dhirajlal Tanna 2. V Square Non- 10,00,000 1,75,000 1,75,000 Rs. 72,18,750 8,25,000 Pharmachem Promoter Private Limited TOTAL 25,50,000 3,05,000 3,05,000 Rs. 1,25,81,250 22,45,000 Pursuant to conversion, the Issued, Subscribed and Paid-up Equity Share Capital of the Company stands increased to Rs. 14,65,08,540/- consis(cid:415)ng of 1,46,50,854 fully paid-up Equity Shares of Rs. 10/- each. The new equity shares so allo(cid:425)ed shall rank pari-passu with the exis(cid:415)ng equity shares of the Company. Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.rela(cid:415)ons@eikolifesciences.com website: www.eikolifesciences.com The informa(cid:415)on in connec(cid:415)on with the allotment of securi(cid:415)es pursuant to Regula(cid:415)on 30 of the SEBI LODR Regula(cid:415)ons read with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure I. The aforesaid in(cid:415)ma(cid:415)on is also being hosted on the website of the Company at www.eikolifesciences.com Request you to take the same on record. // Cer(cid:415)fied True Copy // Eiko LifeSciences Limited Chintan Doshi Company Secretary & Compliance Officer M. No: A36190 Address: 604, Centrum, Opp TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane West 400 604 Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.rela(cid:415)ons@eikolifesciences.com website: www.eikolifesciences.com Annexure-I The details as required under Regula(cid:415)on 30 of SEBI Lis(cid:415)ng Regula(cid:415)ons read with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are as under: Sr. Par(cid:415)culars Disclosure 1. Type of securi(cid:415)es Equity Shares face value of Rs. 10/- (Rupees Ten only) along with premium proposed to be Issued of Rs. 45/- each pursuant to conversion of warrants. 2. Type of issuance Preferen(cid:415)al Allotment Total number of Allotment of 3,05,000 (Three Lakh Five Thousand) Equity Shares at an securi(cid:415)es proposed to issue price of Rs. 55/- each (including a premium of Rs. 45/- each), upon be issued or total conversion for equivalent number of Warrants allo(cid:425)ed at an issue price of amount for which the Rs. 55/- each and upon receipt of balance amount at the rate of Rs. securi(cid:415)es will be issued 41.25/- per warrant (being 75% of the issue price per warrant) aggrega(cid:415)ng to Rs. 1,25,81,250/- (Rupees One Crore Twenty-Five Lakh Eighty-One Thousand Two Hundred Fi(cid:332)y Only) Addi(cid:415)onal informa(cid:415)on in case of preferen(cid:415)al issue: 1. Name of the allo(cid:425)ees 1. Bhavesh Dhirajlal Tanna 2. V Square Pharmachem Private Limited 2. Post allotment of Name of Pre-Issue shareholding Post- Issue shareholding securi(cid:415)es – outcome of Allo(cid:425)ee No. % No. % the subscrip(cid:415)on, issue Bhavesh 8,40,000 5.86% 9,70,000 6.62 price / allo(cid:425)ed price Dhirajlal Tanna (in case of V Square - - 1,75,000 1.19 conver(cid:415)bles), Pharmachem Private Limited 3. Issue Price W arrants had been allo(cid:425)ed on 24th February, 2026 carrying a right to subscribe to one Equity Share per warrant on receipt of amount at the rate of Rs. 13.75/- per warrant (being 25% of the issue price per warrant). Now, 3,05,000 Equity Shares have been allo(cid:425)ed on receipt of balance amount at the rate of Rs. 41.25 per warrant (being 75% of the issue price per warrant) 4. Number of allo(cid:425)ees 2 5. In case of conver(cid:415)bles An amount equivalent to 25% of the warrant issue price has been received - in(cid:415)ma(cid:415)on on at the (cid:415)me of subscrip(cid:415)on and allotment of each Warrant and the balance conversion of 75% amount of the warrant issue price has been received at the (cid:415)me of securi(cid:415)es or on lapse exercise of op(cid:415)on of conversion of warrants in to equity shares by of the tenure of the allo(cid:425)ees to whom the warrants have been allo(cid:425)ed. Consequent to today's instrument conversion of warrants/allotment of Equity Shares, 22,45,000 warrants remain pending for conversion by the two allo(cid:425)ees. Further total Warrants remain pending for Conversion is 26,45,000. ************ Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.rela(cid:415)ons@eikolifesciences.com website: www.eikolifesciences.com